OXFORD_LYMPHOEDEMA_PRACTI - Accounts


Company Registration No. 08474919 (England and Wales)
OXFORD LYMPHOEDEMA PRACTICE LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2019
PAGES FOR FILING WITH REGISTRAR
OXFORD LYMPHOEDEMA PRACTICE LTD
BALANCE SHEET
AS AT
30 APRIL 2019
30 April 2019
- 1 -
2019
2018
Notes
£
£
£
£
Fixed assets
Tangible assets
3
19,132
11,102
Current assets
Debtors
4
131,978
122,174
Cash at bank and in hand
80,134
33,779
212,112
155,953
Creditors: amounts falling due within one year
5
(190,474)
(163,054)
Net current assets/(liabilities)
21,638
(7,101)
Total assets less current liabilities
40,770
4,001
Provisions for liabilities
(3,635)
(2,109)
Net assets
37,135
1,892
Capital and reserves
Called up share capital
6
120
120
Profit and loss reserves
37,015
1,772
Total equity
37,135
1,892

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 30 April 2019 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

OXFORD LYMPHOEDEMA PRACTICE LTD
BALANCE SHEET (CONTINUED)
AS AT
30 APRIL 2019
30 April 2019
- 2 -
The financial statements were approved by the board of directors and authorised for issue on 14 January 2020 and are signed on its behalf by:
Mr Alex Ramsden
Prof Dominic Furniss
Director
Director
Company Registration No. 08474919
OXFORD LYMPHOEDEMA PRACTICE LTD
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 APRIL 2019
- 3 -
Share capital
Profit and loss reserves
Total
Notes
£
£
£
Balance at 1 May 2017
100
15,607
15,707
Year ended 30 April 2018:
Profit and total comprehensive income for the year
-
364,165
364,165
Issue of share capital
6
20
-
20
Dividends
-
(378,000)
(378,000)
Balance at 30 April 2018
120
1,772
1,892
Year ended 30 April 2019:
Profit and total comprehensive income for the year
-
215,243
215,243
Dividends
-
(180,000)
(180,000)
Balance at 30 April 2019
120
37,015
37,135
OXFORD LYMPHOEDEMA PRACTICE LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2019
- 4 -
1
Accounting policies
Company information

Oxford Lymphoedema Practice Ltd is a private company limited by shares incorporated in England and Wales. The registered office is Claremont House, 1 Market Square, Bicester, Oxon, OX26 6AA.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.

 

When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that it is probable will be recovered.

1.3
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures, fittings & equipment
25% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.4
Cash at bank and in hand

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

OXFORD LYMPHOEDEMA PRACTICE LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2019
1
Accounting policies
(Continued)
- 5 -
1.5
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Changes in the fair value of derivatives that are designated and qualify as fair value hedges are recognised in profit or loss immediately, together with any changes in the fair value of the hedged asset or liability that are attributable to the hedged risk.

1.6
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

OXFORD LYMPHOEDEMA PRACTICE LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2019
1
Accounting policies
(Continued)
- 6 -
Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.7
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was 4 (2018 - 4).

3
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 May 2018
33,631
Additions
15,067
Disposals
(9,581)
At 30 April 2019
39,117
Depreciation and impairment
At 1 May 2018
22,529
Depreciation charged in the year
6,230
Eliminated in respect of disposals
(8,774)
At 30 April 2019
19,985
Carrying amount
At 30 April 2019
19,132
At 30 April 2018
11,102
OXFORD LYMPHOEDEMA PRACTICE LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 APRIL 2019
- 7 -
4
Debtors
2019
2018
Amounts falling due within one year:
£
£
Trade debtors
104,820
109,601
Corporation tax recoverable
4,269
-
Other debtors
22,889
12,573
131,978
122,174
5
Creditors: amounts falling due within one year
2019
2018
£
£
Corporation tax
53,433
86,140
Other taxation and social security
3,663
606
Other creditors
133,378
76,308
190,474
163,054
6
Called up share capital
2019
2018
£
£
Ordinary share capital
Issued and fully paid
120 Ordinary shares of £1 each
120
120
7
Directors' transactions

Dividends totalling £132,000 (2018 - £283,500) were paid in the year in respect of shares held by the company's directors.

Advances or credits have been granted by the company to its directors as follows. No interest has been charged on the loans and all loans was repaid within 9 months of the year end:

Description
% Rate
Opening balance
Amounts advanced
Closing balance
£
£
£
Mr Alex Ramsden -
-
4,449
611
5,060
Prof Dominic Furniss -
-
4,500
576
5,076
Dr S Gore -
-
3,000
-
3,000
11,949
1,187
13,136
2019-04-302018-05-01false30 January 2020CCH SoftwareCCH Accounts Production 2019.301No description of principal activityMr A RamsdenDr D FurnissDr S Gore084749192018-05-012019-04-30084749192019-04-30084749192018-04-3008474919core:OtherPropertyPlantEquipment2019-04-3008474919core:OtherPropertyPlantEquipment2018-04-3008474919core:CurrentFinancialInstrumentscore:WithinOneYear2019-04-3008474919core:CurrentFinancialInstrumentscore:WithinOneYear2018-04-3008474919core:CurrentFinancialInstruments2019-04-3008474919core:CurrentFinancialInstruments2018-04-3008474919core:ShareCapital2019-04-3008474919core:ShareCapital2018-04-3008474919core:RetainedEarningsAccumulatedLosses2019-04-3008474919core:RetainedEarningsAccumulatedLosses2018-04-3008474919core:ShareCapital2017-04-3008474919core:RetainedEarningsAccumulatedLosses2017-04-30084749192017-04-3008474919bus:Director12018-05-012019-04-3008474919bus:Director22018-05-012019-04-3008474919core:RetainedEarningsAccumulatedLosses2017-05-012018-04-30084749192017-05-012018-04-3008474919core:RetainedEarningsAccumulatedLosses2018-05-012019-04-3008474919core:ShareCapital2017-05-012018-04-3008474919core:FurnitureFittings2018-05-012019-04-3008474919core:OtherPropertyPlantEquipment2018-04-3008474919core:OtherPropertyPlantEquipment2018-05-012019-04-3008474919core:WithinOneYear2019-04-3008474919core:WithinOneYear2018-04-3008474919bus:PrivateLimitedCompanyLtd2018-05-012019-04-3008474919bus:SmallCompaniesRegimeForAccounts2018-05-012019-04-3008474919bus:FRS1022018-05-012019-04-3008474919bus:AuditExemptWithAccountantsReport2018-05-012019-04-3008474919bus:Director32018-05-012019-04-3008474919bus:FullAccounts2018-05-012019-04-30xbrli:purexbrli:sharesiso4217:GBP